Highly sensitive SD-EAB sensors for point-of-care diagnostic monitoring

Chemotherapy, a cornerstone of cancer treatment, hinges on maintaining precise drug levels in the patient's body. However, the current generalised dosing protocol requires frequent blood draws, is costly, time-consuming, and uncomfortable for patients. To address these issues, we propose an innovative project to develop a finger-prick sensor for instant drug and biomarker monitoring.

This technology leverages a novel approach to electrochemical, aptamer-based sensing, offering a solution that could transform patient monitoring in oncology.

Our primary objective is to design, develop, and validate a sensor to inform dosing of commonly monitored chemotherapies, inspired by recent technologies from the University of Cambridge and 2bind GmbH. Through the ability to select and implement new aptamers, we intend to establish a comprehensive sensor development pipeline. This system will allow commercialisation partners to quickly implement custom sensors for a variety of small molecule targets.

Our project aims to deliver a cutting-edge solution that could revolutionise diagnostic monitoring, starting in oncology and setting a new standard for personalised and patient-centred cancer treatment in the UK and worldwide.